In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

Ulta Beauty ( ULTA) was the best-performing stock in the S&P 500 after the beauty products retailer beat profit and sales ...

The S&P 500 slipped less than 0.1% on Friday, May 30, 2025, as President Trump rekindled his tough rhetoric on China and a ...

Partners Regeneron and Sanofi say itepekimab only achieved a significantly statistic result in one of two studies.

Morgan Stanley has lowered its price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $755 from $958, while ...

Regeneron and Sanofi face setbacks as itepekimab stumbles in phase 3. Click here to read why I believe SNY and REGN stocks ...

On Monday, Truist Securities analysts reiterated their Buy rating for Regeneron Pharma (NASDAQ: NASDAQ:REGN) stock, maintaining ... lack of clarity on subgroup performance in the study.

These factors contribute to the immediate cautious outlook for Regeneron’s stock performance. According to InvestingPro ’s Fair Value analysis, the stock appears undervalued at current levels.

We aim to explore its current performance. With a trading volume of 3,313,559, the price of REGN is down by -18.78%, reaching $491.69. Current RSI values indicate that the stock is may be ...

This performance trails the past year's ... Unlock comprehensive insights into our analysis of Regeneron Pharmaceuticals stock in this financial health report.